The COBE Spectra AutoPBSC collection set (AUTO-kit; CaridianBCT) is a popular dualstage collection set for peripheral blood progenitor (PBPC) collection. Although the AUTO-kit is purportedly equivalent to the white blood cell (WBC) collection set (WBC-kit) for PBPC collection, improved CD34 yields after switching from the AUTO-kit to the WBC-kit were anecdotally observed, particularly in patients with higher WBC counts. A prospective, randomized trial of the AUTO-and WBC-kits for PBPC collection in multiple myeloma (MM) patients was therefore designed.
H igh-dose chemotherapy, followed by autologous peripheral blood progenitor cell transplantation (APBPCT), has become an accepted treatment for many hematologic malignancies, including multiple myeloma (MM). 1, 2 Although not curative, APBPCT can double disease-free survival in MM, with 40% of patients surviving 7 years in some studies. 2, 3 More recent strategies to improve long-term survival include retransplantation, 4, 5 planned tandem APBPCT, [6] [7] [8] allogeneic transplantation, 9 and posttransplant therapy with thalidomide. 10, 11 MM is now the most common indication for APBPCT, 12 with many transplant centers requiring the collection of 6 to 20 million CD34/kg, or sufficient cells to support two to three APBPCTs. 11, 13, 14 At the University of Michigan, MM patients now comprise 52% of all patients and 54% of all PBPC collections.
The rising clinical demand for leukopheresis services has stimulated intense interest in identifying patient, treatment, and technical factors that will improve PBPC mobilization and collection. Factors favoring mobilization are a diagnosis of MM, 15, 16 mobilization with chemotherapy, [17] [18] [19] [20] growth factor dose, 13, 16, 19, 21 the premobilization platelet (PLT) count, 17, 22, 23 and peripheral blood counts (white blood cells [WBCs] , CD34 > 20/mL, PLTs) at the time of leukapheresis. [24] [25] [26] Poor prognostic factors are an older age, female sex, a diagnosis of non-Hodgkin's lymphoma (NHL), extensive prior chemotherapy, and a history of radiation therapy. 17, 18, 27 Although frequently overlooked, procedure-related factors can also impact collection. These include patient vascular access and flow rate, [28] [29] [30] [31] total blood volume (TBV) processed, 15, 27 operator experience, and the specific apheresis device used. 24, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] At the University of Michigan, we have historically used the COBE Spectra blood separator (CaridianBCT, Lakewood, CO) with the AutoPBSC collection set (AUTOkit) and automated mononuclear cell (MNC) software (Version 6.1) for adult collections. The latter is a fully automated program and dual-stage collection set that requires minimal operator intervention, decreased citrate toxicity, less PLT contamination, and reportedly, equivalent or superior collection efficiencies (CEs) to other collection platforms. [40] [41] [42] [43] [44] In 2005, we noted an increase in the number of leukapheresis procedures required for APBPCT, particularly in MM patients with high peripheral WBC counts. In many of these patients, we anecdotally observed improved CD34 collection yields after switching to the WBC collection set (WBC-kit). We therefore designed a prospective randomized trial comparing the performance of the AUTO-kit and WBC-kit in MM patients. We demonstrate that the WBC-kit and chemotherapy mobilization resulted in higher CD34 collection yields, fewer total procedures, and decreased infusion toxicity.
MATERIALS AND METHODS

Patient criteria
All adult MM patients referred for autologous PBPC collection between December 2005 and July 2007 were enrolled. All patients were evaluated and medically cleared for APBPCT according to institutional guidelines before their first leukapheresis procedure. The target yield for all MM patients was 6 ¥ 10 6 CD34 cells/kg or two APBPCTs (3 ¥ 10 6 /kg per transplant). Informed consent for leukapheresis and infectious disease testing was obtained from all patients on the first day of collection. All protocols and consent for PBPC mobilization, collection, and transplantation, including this study, were approved by the institutional review board of the University of Michigan.
Study design
Patients were alternately assigned to either the WBC-kit or AUTO-kit on the first day of apheresis, and all subsequent collections, until the designated target yield of 6 ¥ 10 6 CD34/kg was achieved. 42 During the course of the study, eight patients were randomly assigned to the incorrect group (six to AUTO, two to WBC). Ten patients with poor collection yields (<0.5 ¥ 10 6 CD34/kg/day; CD34/mL > 20) on 2 successive days were switched to the alternate collection kit at the discretion of the apheresis attending physician ("Mixed," Fig. 1 ). Patients failing to collect 6 ¥ 10 6 CD34 cells were remobilized and collected at a later date. In remobilized patients, each mobilization cycle was considered a separate event for postcollection analysis. Only patients collecting at least 3 ¥ 10 6 CD34/kg in a single mobilization cycle were included in postcollection analysis: Mobilization cycles collecting less than 3 ¥ 10 6 Fig. 1 . Study schematic. Sixty-eight MM patients were randomly assigned to either the WBC-kit or AUTO-kit. Each mobilization cycle was considered a separate event for analysis. Altogether, 69 cycles from 63 patients successfully col-CD34/kg were excluded. A total of 17 mobilization cycles, involving nine patients and 57 procedures, were excluded due to poor collection yields (Fig. 1, Table 1 ).
Patient demographic data included patient age, sex, weight, MM subtype, CD34 mobilization regimen, and number of mobilization cycles (Table 2 ). Patient laboratory studies included baseline and Day 1 preapheresis complete blood count (CBC), manual WBC differential, peripheral CD34 count (%CD34, CD34/mL), and total protein and albumin. A daily preapheresis CBC and WBC differential were recorded for all patients requiring more than one procedure. When available, preapheresis quantitative serum immunoglobulin and whole blood viscosity were recorded. Procedure-related data included collection kit (AUTO, WBC), nurse operator, TBV, TBV per body weight (100 mL/kg), cumulative CD34/kg yield, and number of procedures per mobilization cycle (Table 3) . TBV was not corrected for anticoagulant volume.
Mobilization regimens
CD34 mobilization was determined by the patient's attending transplant physician. The majority of patients (70%, Table 2 ) enrolled were collected after chemotherapy, followed by daily granulocyte-colony-stimulating factor (G-CSF; 10 mg/kg/day). 14, 45, 46 Leukapheresis was initiated between 11 and 14 days after chemotherapy when the peripheral WBC count exceeded 5.0 ¥ 10 9 /L. 34, 47 Patients collected after chemotherapy, regardless of specific chemotherapy regimen, were classified as "chemotherapy + growth factor" mobilization (chemo + GF; Table 2 ) for subsequent analysis.
Approximately 30% of patients were mobilized with G-CSF only (10-16 mg/kg/day), starting 4 days before the first leukapheresis procedure (Table 2) . A minority of these patients were mobilized with G-CSF (10 mg/kg) and granulocyte-macrophage-CSF (GM-CSF; 500 mg/day). Patients mobilized with either G-CSF or G-CSF plus GM-CSF were classified as "growth factor only" (GF-only) for purposes of analysis.
Apheresis collections
All leukapheresis procedures were performed on a COBE Spectra blood separator. Venous access was established using a central venous catheter. For patients randomly assigned to the WBC-kit (Software Version 4.7), MNCs were collected by continuous-flow centrifugation, with the blood-plasma interface manually adjusted to a 1% to 2% hematocrit (Hct) using a WBC colorgram (COBE Spectra), a maximum flow rate of 80 mL/min, a whole blood:ACDA ratio of 12:1, and collect volume rate of 1.0 mL per minute. For the AUTO-kit, MNCs were collected using the manufacturer's default software settings (Version 6.1). Harvest volume (5.0 mL), chase volume (5.0 mL), whole blood flow rates, and harvest frequency were determined by the system based on patient size, MNC concentration, and inlet flow rate. 42 Approximately 200 mL of PLT-depleted plasma was collected concurrently. For AUTO-and WBC-kits, three TBVs were processed, averaging 13 L or 162 mL/kg per procedure (Table 3) . To prevent citrate toxicity, all patients received prophylactic calcium gluconate replacement throughout the procedure.
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PLT analysis
The impact of leukapheresis on peripheral PLT counts was monitored by daily preapheresis PLT counts. The transfusion records for all patients were also reviewed for any PLT or RBC transfusion support during the week of PBPC collection.
Product analysis
Volume and WBC count were determined on all products immediately after collection. For units requiring volume reduction, the initial and final volume, WBC count, and percentage of cell loss were recorded ( Table 2 ). The final %MNC and MNCs/kg were determined on all products before freezing. CD34 yields and cell viability were 
Infusion reactions
PBPC infusion records and patient medical records were reviewed for adverse reactions during PBPC infusion. Reactions limited to nausea, vomiting, or fever were labeled as mild. Infusion reactions that included dyspnea, chest tightness, significant hypotension, or hypertension were considered severe.
Engraftment data
Patient medical records were reviewed for WBC and PLT engraftment. WBC, early PLT, and late PLT engraftment were determined as previously described. 47 
Collection in lymphoma patients
As a nonmyeloma control, a retrospective analysis was performed for all adult lymphoma patients undergoing autologous PBPC collection between January 2006 and June 2008. PBPC collections were performed using the AUTO-kit (70%) or mix of AUTO-and WBC-kits (Mixed) between January 2006 and December 2007. Beginning January 2008, the WBC-kit was used for all PBPC collections in our facility. Patients underwent daily leukapheresis for a target yield of 3 ¥ 10 6 CD34/kg. Patient demographic, laboratory data, and product characteristics were collected as described for MM patients. All procedures, including failed mobilizations, were included in the final analysis.
Statistical analysis
Analysis was restricted to successful mobilizations in which at least 3 ¥ 10 6 CD34/kg were collected after a single mobilization. Primary performance measures were the CD34/kg yield and success rate for one and two APBPCTs. Direct comparisons of AUTO-and WBC-kit performance in MM patients were restricted to patients collected solely with the AUTO-or WBC-kit for the entire mobilization cycle: "mixed" collections were excluded. Mixed collections were only included in the aggregate data of all collections. Patient demographic, laboratory, and collection results were reported as the mean Ϯ standard deviation (SD), percentage, median, and range as indicated. The MNC and CD34 CEs (%CE) were calculated as described by Dzieczkowski and coworkers 33 and Ford and coworkers, 31 respectively. Categorical variables were compared primarily by t test unless otherwise indicated. Proportional variables were examined by chi-square (EpiInform, CDC, Atlanta, GA). To determine the significance of individual CD34 collection rates (slope, b), the confidence interval (CI) for each slope was calculated using the appropriate critical t values (t*) at t(n -2) distribution, where
Univariate statistics (t test, paired t test, Mann-Whitney U test), correlation coefficient (R), correlation probabilities, 
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linear regression including t-probabilities and standard error, and graphics were performed with commercial software (Kaleidograph, Synergy Software, Reading, PA). A p value of less than 0.05 was considered significant.
RESULTS
Patient demographics
Between December 2005 and July 2007, a total of 68 MM patients underwent autologous PBPC collection at our facility. Sixty-three patients (93%), who successfully collected at least 3 ¥ 10 6 CD34 cells/kg in a single mobilization, were included in the final analysis. Six patients required a second mobilization to reach 6 ¥ 10 6 CD34/kg or two APBPCTs. Altogether, 69 mobilization cycles and 189 procedures were available for analysis.
Seventeen mobilizations were excluded from the final analysis, including 14 cycles from six patients with multiple poor mobilizations and three cycles from three patients who had one prior successful collection but failed to remobilize after additional chemotherapy and GF-only mobilization (Fig. 1) . Excluded cycles were associated with GF-only mobilization (p = 0.002), low CD34/mL (p < 0.0001), and poor CD34/kg yields (p < 0.001). Many patients had risk factors for poor mobilization including prior radiotherapy and extensive chemotherapy (Table 1) . 17, 18, 27 For analysis, each successful collection was classified by the type of kit used, WBC-kit or AUTO-kit, during the entire mobilization collection cycle. Mixed collections, in which patients were switched to the alternate collection set, were only included in the aggregate data of all collections (All), regardless of collection set. As shown in Tables 2 and 3 , there was no significant difference in patient age, sex, weight, or TBV processed between collection kits. Approximately 70% of all patients, regardless of kit, were collected after chemotherapy (chemo + GF) while the remaining 30% were mobilized with GF-only. The AUTO-kit group had a higher percentage of patients mobilized with DT-PACE (52%), which we have shown to be equivalent to cyclophosphamide for PBPC mobilization in MM. 46 
Peripheral blood counts
The CBC, %MNCs, and CD34 counts on the first day of collection, and for all procedures in aggregate, were compared by kit (Table 3 ) and mobilization regimen (Table 4) . There was no significant difference in peripheral WBC, %MNC, %Hct, and PLT and CD34 counts between kits, although AUTO-kit patients had a higher mean %CD34 (Table 3) . Patients mobilized with GF-only had a higher mean WBC count whereas chemo + GF patients had significantly higher peripheral CD34 counts (Table 4) .
Product characteristics
PBPC products collected with the WBC-kit had a greater initial volume and WBC count, on average, than the AUTO-kit (Table 3) . [40] [41] [42] [43] Volume reduction was performed on 45% of AUTO-kit and 77% of WBC-kit products before freezing. After processing, there was no significant difference in volume or WBC count between collection kits although some degree of cell loss (1%-29%) was documented in 25% of AUTO-and 51% of WBC-kit units. Seven patients had greater than 10% cell loss in multiple successive collections. There was no correlation between cell loss, collection kit, MM subtype, laboratory studies, or mobilization regimen in these patients (data not shown).
An initial analysis of CD34 yield by collection kit suggested improved performance with the WBC-kit ( Table 3 ). The WBC-kit had a higher mean %CD34 and CD34/kg yield per unit and a 23% higher CD34/kg yield per mobilization cycle (p = 0.048) than the AUTO-kit.
CD34/kg yield by day and collection kit
We initially examined the CD34/kg yield per procedure by mobilization regimen, collection kit, and collection day ( Fig. 2A) . Without exception, patients mobilized with chemo + GF collected 40% to 60% more CD34 cells per collection day (p = 0.016-0.044), and per cycle (Table 4) , over GF-only patients. When subanalyzed by collection kit, mean CD34/kg yields tended to be higher with chemo + GF mobilization and WBC-kit, particularly on Day 3 (CD34/kg = 2.35 vs. 1, p = 0.02). Similar findings were observed when mixed collections (Fig. 1) were included in the analysis (p = 0.0019, not shown). The mean CD34/kg yield per cycle was also higher in chemo + GF patients using the WBC-kit (CD34/kg 13.4 vs. 9.6, p = 0.09). In GF-only patients, the total CD34/kg yield was slightly better with the AUTO-kit (p = 0.03) although there was no significant difference per collection day between kits (Fig. 2A) .
Number of procedures for one APBPCT
The minimum number of procedures required to collect 3 ¥ 10 6 CD34/kg or one APBPCT, and the total number of procedures per cycle, were compared by mobilization regimen and kit (Fig. 2, Table 4 ). As expected, patients mobilized with chemo + GF underwent fewer procedures than GF-only patients, with 46% to 67% collecting one APBPCT in one procedure (Fig. 2B, Number collecting one APBPCT in one procedure (%)
28 (46) 12 (67) 16 (64) 2 (12) 1 (17) 1 (10) 0.0003 § Number collecting two APBPCTs in one mobilization (%)
27 (56) 17 (94) ¶
18 (72) 9 (43) 1 (17) 5 (50) 0 successfully collected for one APBPCT with the WBC-kit per procedure (Fig. 2B) .
Number of procedures for two APBPCTs
We also examined the success rate to collect 6 ¥ 10 6 CD34/kg in a single mobilization cycle (Fig. 2C, Table 3 ). Overall, 82% of chemo + GF-versus 37% of GF-onlymobilized patients collected two APBPCT in a single mobilization cycle (p = 0.001; OR, 7.29; 95% CI, 1.75-32.22). In chemo + GF patients, more patients collected for two APBPCTs with the WBC-kit (94% vs. 72%, p = 0.06), with 50% collecting in one procedure.
CD34 collection rate
Despite equivalent peripheral CD34 counts and MNC-CE (Table 3) , CD34/kg yields tended to be consistently higher with the WBC-kit in chemo + GF-mobilized patients. To explain the latter, we plotted the CD34/kg yield per peripheral CD34 count by kit and mobilization regimen (Figs. 3A and 3B). As reported, there was a linear correlation between CD34 count (CD34/mL) and CD34/kg yield when all collections were examined (Fig. 3A) . 24 When examined by kit and mobilization regimen, the fastest CD34 collection rate (slope) was observed using chemo + GF mobilization and WBC-kit. The results were more dramatic when CD34/kg yields were plotted by %CD34 cells (Fig. 3B , p < 0.05). In chemo + GF patients, a nonlinear relationship was noted with the WBC-kit, resulting in high CD34/kg yields despite low circulating %CD34 cells.
Comparison of CD34 collection in individual patients
A few patients were remobilized and collected using the alternate collection set, including two patients excluded from the final analysis due to poor collection yields (Figs. 3C through 3E) . In all patients, the WBC-kit collected more CD34 cells than the AUTO-kit in the first 2 days of collection, regardless of mobilization regimen used (p = 0.003, paired t test). The improved collection with the WBC-kit was particularly noteworthy in patients 55 and 128, in which two different mobilization regimens were used.
Effect of peripheral WBC count on CD34 collection
Five prior studies have reported a decrease in MNC-CE and CD34-CE at elevated peripheral WBC and CD34 counts, particularly at WBC counts greater than 20 ¥ 10 9 / L. 26, [30] [31] 38, 51 Similarly, we had observed decreased CD34/kg yields and CD34 collection rates in GF-only patients (Fig. 3) , who typically had higher peripheral WBC counts (Table 4) . To explore whether WBC count impacted CD34 collection, the mean CD34/kg yield and CD34 collection rate were compared at "high" (>20 ¥ 10 9 /L) and "low" (<20 ¥ 10 9 /L) WBC counts as defined by Gidron and colleagues. 51 In general, the mean CD34/kg yield decreased with increasing peripheral WBC count (Fig. 4A) . We also observed a drop in MNC-CE and CD34-CE at high WBC counts with both kits, with a 50% decrease in CD34-CE with the AUTO-kit (Table 5 ). The impact of WBC count on CD34 collection was also evident when CD34 collection rate was plotted at high and low WBC counts. Specifically, high WBC counts were associated with a 50% decrease in CD34 collection rate or slope using the AUTO-kit (Fig. 4B , p < 0.01). In contrast, high WBC counts had no apparent effect on CD34 collection rates with the WBC-kit (Fig. 4C , p = NS).
We examined several factors that could potentially impact blood viscosity, laminar flow, and MNC collection in the AUTO-kit design (Table 5) . 52 As expected, high WBC counts were associated with GF-only mobilization. Higher WBC counts were accompanied by higher PLT and RBC counts, particularly in GF-only patients who typically displayed a parallel increase between WBC counts, Hct levels (R = 0.36, p = 0.0014; Fig. 4C ), and PLT counts (R = 0.49, p = 0.03; not shown). In GF-only patients, there was an inverse relationship between Hct and %MNC-CE with the AUTO-kit (Fig. 4D) . Hct, however, had no independent effect on CD34 collection rates (Fig. 4E) . There was no correlation between %MNC-CE, %CD34-CE, CD34 yield, and CD34 collection rates with either premobilization or daily PLT counts (not shown), 17, 22, 23 serum protein, albumin, 31 or immunoglobulin levels. A recent fibrinogen, C-reactive protein, or whole blood viscosity was not available for analysis in most patients.
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CD34 collection in lymphoma patients by collection set
To test whether our observations were unique to MM patients, we performed a retrospective analysis of PBPC collection in adult autologous lymphoma patients. Unlike MM patients, lymphoma patients were a very heterogenous population with a wide range in patient age, prior treatment (not shown), chemotherapy-associated mobilization, and mobilization failures 53, 54 (Table 6 ). In general, slightly more lymphoma patients collected in one procedure with the WBC-kit (Fig. 5A) . When normalized for peripheral CD34 counts, the WBC-kit performed slightly better than the AUTO-kit (Fig. 5B) . In Hodgkin's lymphoma, a nonlinear relationship was again observed between CD34 yields and %CD34 cells (Fig. 5C, p < 0.01) . In contrast to MM, the peripheral WBC count had no impact on CD34 collection rates in lymphoma patients (Fig. 5D, p = NS) . 
Effect of collection kit on PLT counts
One stated disadvantage of the WBC-kit for PBPC collection is the risk of procedure-related thrombocytopenia, with some studies reporting a 30% to 43% decrease in PLT count per procedure. [40] [41] [42] 55, 56 To examine the latter, we calculated the absolute and percentage change in daily PLT count. The mean decrease in daily PLT count was 12% (range, 0% to 53%) with no significant difference between kits ( Table 3 ). The AUTO-kit, however, had the greatest intrapatient change in PLT count (p = 0.0005 vs. WBC-kit, p = 0.05; paired t test).
We also reviewed the transfusion record of each patient for any PLT or RBC transfusions during the course 
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of PBPC collection (Table 3) . Only one patient required a PLT transfusion. This patient received a PLT transfusion the day before starting PBPC collection for a PLT count of 12 ¥ 10 9 /L. This patient underwent four procedures using the WBC-kit without additional transfusion support. No patient studied required a RBC transfusion during the course of PBPC collection.
Infusion reaction rate by kit and mobilization
Most patients underwent at least one APBPCT and 30% received two APBPCTs, for a total of 88 infusions ( Table 7 ). The mean reaction rate for all infusions was 26%, with a higher reaction rate with AUTO-kit units (33%). Most reactions were mild and included nausea and vomiting (83%), cough (17%), cramps (9%), fever, and rigors (4%). Five reactions were relatively severe with cardiopulmonary symptoms. Reactions were significantly associated with GF-only mobilization (p < 0.0001; relative risk, 4.1; OR, 8.1; 95% CI, 2.4-27.9). Although GF-only patients accounted for only 25% of all APBPCTs, they comprised nearly 60% (13/23) of all infusion reactions.
Prior studies have reported a link between PBPC infusion reactions, DMSO dose, and the number of contaminating granulocytes. [57] [58] [59] [60] In general, the total granulocyte yield (3.61 ¥ 10 9 ; p = 0.0001), granulocytes/kg (4.07 ¥ 10 7 ; p = 0.0001), and volume infused (417 mL) were higher in units associated with infusion reactions (Fig. 6) . When reactions were examined by mobilization regimen, the granulocyte dose and volume were significantly higher in GF-only units (p < 0.00001), particularly when collected with the AUTO-kit (5.19 ¥ 10 7 granulocytes/kg, p = 0.0006). Among severe reactions, granulocyte doses averaged 6.31 ¥ 10 7 /kg for GF-only units collected with the AUTO-kit.
Engraftment
All patients received an equivalent CD34/kg dose per transplant, regardless of collection kit or mobilization regimen. There was no significant difference in time to WBC or PLT engraftment. Engraftment times were consistent with previously published studies from our institution.
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DISCUSSION
Several semi-and fully automated apheresis platforms are available for the collection of peripheral CD34 cells. [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Since its introduction in 1998, the AUTO-kit has been broadly implemented at many institutions. Among the cited advantages of the AUTO-kit are an automated interface and anticoagulant management, increased interface stability, decreased operator oversight, decreased citrate reaction rates, a smaller product volume, and increased product purity with reductions in PLT and granulocyte contamination. [40] [41] [42] Observed disadvantages of the AUTOkit are an increase in collection time, technical difficulties leading to skipped MNC harvests, and inferior collection yields at low peripheral CD34 counts. 39, 40, 42 Although we had routinely used the AUTO-kit in adult patients since January 1998, we used the WBC-kit for PBPC collection in children, in remobilized patients, and in adults with falling collection yields. Because the WBCkit was anecdotally associated with improved collection yields in many patients, we designed a prospective randomized trial using the WBC-kit or AUTO-kit in MM patients undergoing autologous PBPC collection. MM patients were chosen because they have a low rate of mobilization failure and represent a relatively homogenous patient population with regard to age, pretreatment chemotherapy, and mobilization regimens. In addition, MM represents the majority (52%) of all adult APBPCT patients at our institution. Finally, MM may represent a technically unique patient population due to circulating paraprotein, which could impact blood viscosity, cell separation, and elutriation. 52 Because of the impact of mobilization regimen on CD34 mobilization, [17] [18] [19] [20] results were analyzed by both collection kit and mobilization. We also performed a retrospective review of AUTO-and WBCkit performance in adult lymphoma patients as a nonmyeloma control.
As expected, mobilization regimen was the single greatest factor affecting CD34 collection. Patients collected with chemo + GF had significantly higher CD34 counts, higher CD34 yields, and fewer total procedures than patients mobilized with GF-only (Table 4) . collection rates (slope) at 95% and 99% CI. 50 
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Chemo + GF patients were also more likely to collect sufficient CD34+ cells for two transplants (Fig. 2 , Table 4 ). Although some authors have claimed equivalent CD34 collections with GF-only, [61] [62] [63] our results agree with more recent studies showing improved mobilization with chemo + GF in MM. 18, 19 Contrary to recent reports, 17, 22, 23 neither premobilization nor Day 1 PLT counts were helpful in predicting successful CD34 collection, probably because the highest PLT counts were associated with GF-only mobilization (p = 0.0005, Table 3 ). We also observed a higher daily success rates with the WBC-kit in chemo + GF-mobilized patients. Overall, 10% to 15% more patients successfully collected per procedure with the WBC-kit, with more than 90% collecting for two APBPCTs (Fig. 2, Table 3 ). Even among poor mobilizers, the WBC-kit resulted in higher daily CD34/kg yields despite dismal peripheral CD34 counts and CD34/kg yields (Fig. 2D,E) . These results agree with Morton and colleagues 37 who observed a higher success rate per collection with the WBC-kit over the Haemonetics MCS-3P, especially for target yields of greater than 5 ¥ 10 6 CD34/kg. They also agree with Wilke and coworkers 39 who reported comparatively better CD34 yields with the WBC-kit at low CD34 concentrations (<10 CD34/mL, p = 0.012). Although some centers have been reluctant to use the WBC-kit due to concerns of procedure-related thrombocytopenia, 35, 41, 55, 56 we did not encounter clinically significant thrombocytopenia in our patients in agreement with other investigators (Table 2) . 34, 43 The WBC-kit also displayed a higher CD34 collection rate in certain populations, depending on underlying disease and mobilization regimen. Specifically, the CD34/kg collection rate per peripheral CD34/mL count was twofold higher with the WBC-kit in chemo + GF MM and Hodgkin's lymphoma patients ( Fig. 3 and 5) . When examined by peripheral %CD34, the CD34 collection was nonlinear, resulting in high CD34/kg yields even at relatively low CD34 concentrations. These results were not observed in NHL and GF-only-mobilized MM patients.
Finally, the WBC-kit appeared less sensitive than the AUTO-kit to high peripheral WBC counts. Although both kits exhibited a decrease in MNC-CE and CD34-CE with increasing peripheral WBC counts (Table 4) , the impact was worse with the AUTO-kit. The AUTO-kit had a 50% decrease in CD34-CE at WBC counts greater than 20 ¥ 10 9 /L, accompanied by a twofold decrease in CD34 collection rate (Fig. 3, p < 0.01) . The decrease in CD34 collection rate was not observed with the WBC-kit, or in lymphoma patients, suggesting that the phenomenon is unique for the AUTO-kit in MM.
A potential adverse effect by elevated peripheral WBC and MNC counts on CE has been reported by others. 26, 30, 31, 38, 51 In an early study, Benjamin and colleagues 27 noted an inverse relationship between the peripheral MNC count and MNC-CE, with the best CE observed at low WBC and MNC counts. Similar findings were reported by Heuft and colleagues 38 and Gidron and colleagues, 51 who noted a decrease in the calculated CD34-CE at higher WBC and CD34 counts. Gidron, in particular, reported a significant decrease in CD34-CE at peripheral WBCs greater than 20 ¥ 10 9 /L (p < 0.0001), prompting the authors to caution against GF-only mobilization regimens. 51 Finally, Burgstaler and colleagues 30 reported a significant decrease in CD34 yields (55%-77%), accompanied by a twofold increase in WBC contamination, in units collected at WBC counts of greater than 35 ¥ 10 9 /L and flow rates greater than 60 mL/min.
Benjamin and coworkers 26 hypothesized that all continuous flow centrifugation devices may be susceptible to a fall-off in CE with rising WBC and CD34 counts due to the fixed size of the collection aperture. These authors speculated that at low WBC counts, the MNC band is narrow relative to the collection channel, permitting an efficient collection of the entire MNC layer. CE decreases with increasing MNC and WBC counts as the MNC layer exceeds the fixed diameter of the collection channel and an increasing percentage of MNC escape collection. Our results suggest that the dual-stage design of the AUTO-kit may exacerbate the effect of elevated WBC on CD34 collection rate and efficiency in MM patients.
Several factors could synergistically depress CE with the AUTO-kit design in GF-only mobilized MM patients via effects on blood viscosity, laminar flow, and cell separation. Blood viscosity is sensitive to increases in Hct, WBCs, PLTs, fibrinogen, immunoglobulin, and other plasma proteins. 52 Hct and leukocrit, in particular, are major and synergistic contributors to whole blood viscosity, that are both increased with GF-only mobilization. The additional impact of paraprotein is variable; however, blood viscosity is elevated in more than 50% of MM patients when corrected for Hct. 52 G-CSF may further increase plasma and whole blood viscosity due to increases in fibrinogen, Factor VIII and von Willebrand factor, PLT count, and PLT activation. [64] [65] [66] In the Fenwal Amicus, high PLT counts and increased plasma viscosity are both theorized to interfere with cell collection, leading to decreased MNC-CE, lower CD34/kg yields, and missed collection cycles. 67 Although we were unable to demonstrate a direct association between CD34 collection and paraprotein levels, it is noteworthy that only MM patients demonstrated a drop in the CD34 collection rate at high WBC counts.
Finally, we compared infusion and engraftment data by kit and mobilization. All patients were transplanted with equivalent CD34/kg doses and had similar engraftment times. There was, however, a higher incidence of infusion reactions, accompanied by a higher granulocyte dose per APBPCT, with GF-only units. Zambelli and colleagues were the first to report an association between fever and granulocyte dose (>10 9 /kg), 57, 58 followed by Calmels and coworkers, 59 who reported a higher median granulocyte content (3.3 ¥ 10 9 ) in units associated with adverse reactions. Likewise, we observed a significantly higher total granulocyte content and granulocyte/kg dose with infusion reactions, particularly with GF-only units (Fig. 6) .
Our study differs significantly from prior studies examining the AUTO-kit, [39] [40] [41] [42] [43] [44] and other collection platforms, both in design and in postcollection analysis. Although primary disease and mobilization regimen are known to be significant factors influencing CD34 mobilization, [16] [17] [18] [19] [20] most studies have examined device performance in a heterogenous pool of patients and normal donors, often using historical data for comparison purposes. [34] [35] [36] [37] [38] [39] [41] [42] [43] A few studies have performed 2-day randomized crossover studies to control for patient-related factors. [34] [35] [36] [37] 43 Although there are many advantages to a crossover design, our study allowed us to compare the collection kit performance over several consecutive days in individual patients. As a consequence, we were able to extend our analysis to the number of procedures/ mobilization, the success rate per APBPCT, and infusion reaction rate. Our results highlight the need to consider the impact of patient diagnosis, mobilization regimen, and CD34 collection rates in the evaluation of new apheresis devices.
In summary, we have performed the first randomized, prospective study specifically comparing the AUTO-and WBC-kits for PBPC collection in MM. We demonstrate that the WBC-kit, combined with chemo + GF mobilization, improves CD34 yields in MM patients. GF-only mobilization was associated with more procedures and decreased CE, particularly with the AUTO-kit due to a fall-off in CD34 collection rates at higher WBC counts. We also showed an increase in infusion reaction rates and higher granulocyte doses with GF-only and AUTO-kit units. Because MM patients represent a significant proportion of our transplant population, we have discontinued the use of the AUTO-kit for all collections. In addition, there has been a significant shift toward chemo + GF mobilization for all patients unless medically contraindicated.
